Office:
103 Carnegie Center, Suite 103
 
Princeton, NJ 08540,USA
Phone:
(609) 799-0050
Fax:
(609) 497-9695

 

 

 

Sebastian Wanless, M.D.
Member of the Scientific Advisory Board

After qualifying as a physician in Edinburgh, Scotland, Dr. Wanless began both clinical work and research activities. In 1980, he moved to the south of England and completed a PhD in cardiovascular physiology at the University of London in 1984. The PhD involved both clinical and preclinical elements. Thereafter he obtained funding from the British Heart Foundation to continue basic research on heart failure. In 1986 he joined the Bristol-Myers Pharmaceutical Company and worked in clinical research for 17 years, assuming increasing levels of responsibility and international experience in Western Europe, the U.S., Japan and Eastern Europe, ending up as a V.P. based in the U.S.

Throughout these 17 years, he gained wide experience in the design of country-specific drug development programs, clinical trial design and implementation. This was perhaps reflected most clearly by his championing of innovative drug development programs in Japan between 1989 and 1992, involving the use of data derived from the U.S. and Europe. Following his time in Japan, he took up a role as in Brussels as Director of Cardiovascular Research and succeeded in creating a Europe-wide approach to trial design and implementation providing large amounts of data for both European and U.S. drug filings. In 1995 he was appointed as Executive Director of Research for Eastern Europe. In this role he supervised the creation from scratch of a highly productive infrastructure and workforce in 12 Eastern European countries. In 1998, he was promoted to V.P. of Intercontinental Research, responsible for all Bristol-Myers Squibb research conducted in Canada, Latin America, Africa and Asia, as well as providing medical affairs support for the company’s business in all these geographic areas. In 2001, he was appointed V.P. of Global Standards and Bioethics, a new entity in the research organization. This incorporated clinical and laboratory compliance, research standards and training across the organization and the organization’s Bioethics Committee, which was created on his proposal to ensure that research at BMS would be conducted according to the highest bioethical standards. Throughout his time in research, Dr. Wanless led extensive programs of investigator capacity building in terms of the conduct of clinical trials according to Good Clinical Practice.

In 2003 he transferred to work for the Bristol-Myers Squibb Foundation and over the past eight years his work has been dedicated to the fight against HIV, initially in Africa and more recently in Romania in addition. From July 2003 until September 2007 he served as Senior Medical Director of the Bristol-Myers Squibb funded “Secure the Future” program based in Johannesburg, South Africa. This was a $150 million donation for HIV related medical research and community programs in nine Sub-Saharan Africa countries. This was because of personal motivation to contribute to mitigating the disastrous effects of the epidemic. During his time as Director of “Secure the Future”, he supervised 66 community-based programs, including importantly those programs’ M&E frameworks. He also oversaw 63 clinical and operational research programs.

In September 2007 he retired from this role and subsequently took up the role as V.P. Research and program Evaluation for the Baylor international Pediatric AIDS Initiative (BIPAI), dedicated to the care and treatment of children with HIV/AIDS in Romania and Africa. As such he continued to travel extensively in Africa overseeing programs in seven countries. His responsibilities lead him to 1) Oversee 61 operational and clinical research studies throughout the network, 2) create an innovative M&E framework for the Baylor International Pediatric AIDS Initiative (BIPAI). The framework included extensive analysis of clinical outcomes and evaluation of organizational performance according to the Balanced Score Card approach, 3) conduct strategic planning processes for all Children’s Clinical Centers of Excellence within the BIPAI network in Africa, 4) conduct annual impact evaluations of performance at BIPAI Children’s Centers of Excellence in Africa and 5) provide training in research methodology, Good Clinical Practice and Monitoring and Evaluation.

Based on Dr. Wanless’s extensive experience as summarized above, he is expertly qualified to provide the following services as a consultant: 1) Clinical and operational research design, 2) international clinical trial implementation, 3) design and implementation of monitoring and evaluation frameworks, 4) organizational strategic planning and 5) training in research methodology, Good clinical Practice and monitoring and evaluation.


   

All rights reserved.